advanced search

<< Back To Home

NEW THIS FRIDAY: THE GLOBAL BURDEN OF HEPATITIS E VIRUS GENOTYPES 1 AND 2 IN 2005

Wednesday, 14th of August 2013

• THE GLOBAL BURDEN OF HEPATITIS E VIRUS GENOTYPES 1 AND 2 IN 2005

Hepatology, Volume 55, Issue 4, pages 988–997, April 2012

Additional Information

How to Cite

Rein, D. B., Stevens, G. A., Theaker, J., Wittenborn, J. S. and Wiersma, S. T. (2012), The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology, 55: 988–997. doi: 10.1002/hep.25505

Author Information

1. ¹ NORC at the University of Chicago (Atlanta, GA location), Atlanta, GA
2. ² World Health Organization, Geneva, Switzerland
3. ³ RTI International, Research Triangle Park, NC

1. ^‡ *Gretchen Stevens and Steven T. Wiersma are staff members of WHO. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of WHO.

Email: David B. Rein (david-rein@norc.org)

^*NORC, 1045 Maryland Avenue, Atlanta, GA 30306

• ^† Potential conflict of interest: Nothing to report.
• ^‡ *Gretchen Stevens and Steven T. Wiersma are staff members of WHO. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of WHO.
• ^§ Supported by the Expanded Programme on Immunization (EPI), Department of Immunization, Vaccines and Biologicals (IVB), Family and Community Health (FCH), World Health Organization, through Agreement for Performance of Work (APW) Ref. no. I8-APW-189.

Abstract below; full text is at http://onlinelibrary.wiley.com/doi/10.1002/hep.25505/full

 

We estimated the global burden of hepatitis E virus (HEV) genotypes 1 and 2 in 2005. HEV is an emergent waterborne infection that causes source-originated epidemics of acute disease with a case fatality rate thought to vary by age and pregnancy status. To create our estimates, we modeled the annual disease burden of HEV genotypes 1 and 2 for 9 of 21 regions defined for the Global Burden of Diseases, Injuries, and Risk Factors Study (the GBD 2010 Study), which represent 71% of the worlds population. We estimated the seroprevalence of anti-HEV antibody and annual incidence of infection for each region using data from 37 published national studies and the DISMOD 3, a generic disease model designed for the GBD Study. We converted incident infections into three mutually exclusive results of infection: (1) asymptomatic episodes, (2) symptomatic disease, and (3) death from HEV. We also estimated incremental cases of stillbirths among infected pregnant women. For 2005, we estimated 20.1 (95% credible interval [Cr.I.]: 2.8-37.0) million incident HEV infections across the nine GBD Regions, resulting in 3.4 (95% Cr.I.: 0.5-6.5) million symptomatic cases, 70,000 (95% Cr.I.: 12,400-132,732) deaths, and 3,000 (95% Cr.I.: 1,892-4,424) stillbirths. We estimated a probability of symptomatic illness given infection of 0.198 (95% Cr.I.: 0.167-0.229) and a probability of death given symptomatic illness of 0.019 (95% Cr.I.: 0.017-0.021) for nonpregnant cases and 0.198 (95% Cr.I.: 0.169-0.227) for pregnant cases.

 

Conclusion: The model was most sensitive to estimates of age-specific incidence of HEV disease.